Dod Biotech Public Stock Gross Profit
| DOD Stock | 2.10 0.12 5.41% |
DOD Biotech Public fundamentals help investors to digest information that contributes to DOD Biotech's financial success or failures. It also enables traders to predict the movement of DOD Stock. The fundamental analysis module provides a way to measure DOD Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DOD Biotech stock.
DOD |
DOD Biotech Public Company Gross Profit Analysis
DOD Biotech's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current DOD Biotech Gross Profit | 437.65 M |
Most of DOD Biotech's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DOD Biotech Public is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, DOD Biotech Public reported 437.65 M of gross profit. This is 95.63% lower than that of the Consumer Defensive sector and 75.05% lower than that of the Packaged Foods industry. The gross profit for all Thailand stocks is 98.4% higher than that of the company.
DOD Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DOD Biotech's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DOD Biotech could also be used in its relative valuation, which is a method of valuing DOD Biotech by comparing valuation metrics of similar companies.DOD Biotech is currently under evaluation in gross profit category among its peers.
DOD Fundamentals
| Return On Equity | 0.04 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.10 % | |||
| Current Valuation | 2.04 B | |||
| Shares Outstanding | 410 M | |||
| Shares Owned By Insiders | 48.01 % | |||
| Shares Owned By Institutions | 2.38 % | |||
| Price To Book | 1.47 X | |||
| Price To Sales | 2.55 X | |||
| Revenue | 1.02 B | |||
| Gross Profit | 437.65 M | |||
| EBITDA | 338.82 M | |||
| Net Income | 49.79 M | |||
| Total Debt | 19.31 M | |||
| Book Value Per Share | 3.03 X | |||
| Cash Flow From Operations | 145 M | |||
| Earnings Per Share | 0.12 X | |||
| Target Price | 14.0 | |||
| Beta | 1.3 | |||
| Market Capitalization | 2.17 B | |||
| Total Asset | 1.63 B | |||
| Z Score | 67.2 | |||
| Net Asset | 1.63 B |
About DOD Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DOD Biotech Public's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DOD Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DOD Biotech Public based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in DOD Stock
DOD Biotech financial ratios help investors to determine whether DOD Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DOD with respect to the benefits of owning DOD Biotech security.